NCT04442087 (FamilyPEDCOVID) is a NA clinical trial of Serology SARS-CoV2 in SARS-CoV2, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT04442087?

NCT04442087 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT04442087?

Interventions in NCT04442087: Serology SARS-CoV2, Data collection.

Is NCT04442087 still recruiting?

NCT04442087 is currently completed. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT04442087: FamilyPEDCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP

Completed NA Last updated 20 November 2025

What this trial tests

NA trial testing Serology SARS-CoV2 in SARS-CoV2 in 563 participants. Completed in 30 April 2021.

Timeline

19 June 2020

Primary endpoint
30 April 2021

30 April 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	563
Start date	19 June 2020
Primary completion	30 April 2021
Estimated completion	30 April 2021
Sites	1 location across France

Drugs / interventions tested

Serology SARS-CoV2 — full drug profile →
Data collection — full drug profile →

Conditions studied

SARS-CoV2 — all drugs for SARS-CoV2 →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Eligibility, any sex, with SARS-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to define seroprevalence of anti-SARS-CoV2 among children of Hospital Workers in APHP, particularly exposed population, according to parents' SARS-CoV2 serological status.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04442087 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04442087.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing